Candriam S.C.A. I Mab Transaction History
Candriam S.C.A.
- $16.8 Billion
- Q2 2025
A detailed history of Candriam S.C.A. transactions in I Mab stock. As of the latest transaction made, Candriam S.C.A. holds 1,132,563 shares of IMAB stock, worth $4.89 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,132,563Holding current value
$4.89 Million% of portfolio
0.02%Shares
3 transactions
Others Institutions Holding IMAB
# of Institutions
41Shares Held
14.2MCall Options Held
10.2KPut Options Held
0-
Hhlr Advisors, Ltd. Grand Cayman, E95.98MShares$25.8 Million0.6% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC4.17MShares$18 Million3.04% of portfolio
-
Sg Americas Securities, LLC876KShares$3.79 Million0.01% of portfolio
-
International Biotechnology Trust PLC London, X0310KShares$1.34 Million0.14% of portfolio
-
Edbi Pte LTD Singapore, U0222KShares$959,6270.2% of portfolio
About I-Mab
- Ticker IMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,098,800
- Market Cap $359M
- Description
- I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...